Hydroxychloroquine, COVID-19 and diabetes. Why it is a different story.

Abstract

Hydroxychloroquine has been proposed for the cure of the COVID-19 due to its anti-inflammatory and anti-viral action. People with diabetes are more prone to severe outcome if affected by COVID-19 and the use of Hydroxychloroquine might have some benefit in this setting. However, the use of Hydroxychloroquine in diabetes deserves particular attention for its documented hypoglycemic action.

• Authors: Anca Pantea Stoian, Doina Catrinoiu, Manfredi Rizzo, Antonio Ceriello
• Journal: Diabetes/metabolism research and reviews (Diabetes Metab Res Rev) Vol. 37 Issue 2 Pg. e3379 (02 2021) ISSN: 1520-7560 [Electronic] England
• PMID: 32592507 (Publication Type: Journal Article)
• Copyright: © 2020 John Wiley & Sons Ltd.

Chemical References

• Blood Glucose
• Hypoglycemic Agents
• Hydroxychloroquine

Topics

• Blood Glucose (drug effects, metabolism)
• COVID-19 (blood, epidemiology, pathology)
• Diabetes Complications (drug therapy, epidemiology)
• Diabetes Mellitus (blood, drug therapy, epidemiology)
• Glycemic Control (methods)
• Humans
• Hydroxychloroquine (therapeutic use)
• Hypoglycemic Agents (therapeutic use)
• SARS-CoV-2 (drug effects)
• Severity of Illness Index
• Signal Transduction (drug effects)
• COVID-19 Drug Treatment